Cargando…
S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer
Microtubule-targeting agents are widely used as active anticancer drugs. However, drug resistance always emerges after their long-term use, especially in the case of paclitaxel, which is the cornerstone of all subtypes of breast cancer treatment. Hence, the development of novel agents to overcome th...
Autores principales: | Hou, Zhenyan, Lin, Songwen, Du, Tingting, Wang, Mingjin, Wang, Weida, You, Shen, Xue, Nina, Liu, Yichen, Ji, Ming, Xu, Heng, Chen, Xiaoguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221130/ https://www.ncbi.nlm.nih.gov/pubmed/37242532 http://dx.doi.org/10.3390/ph16050749 |
Ejemplares similares
-
SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling
por: Wang, Weida, et al.
Publicado: (2023) -
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived suppressor cells
por: Wang, Mingjin, et al.
Publicado: (2023) -
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015) -
C9orf72 in myeloid cells suppresses STING-induced inflammation
por: McCauley, Madelyn E., et al.
Publicado: (2020) -
Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis
por: Das, Lalita, et al.
Publicado: (2012)